Results 101 to 110 of about 4,640 (210)

Dexamethasone/Selinexor Regimen [PDF]

, 2020
openaire   +1 more source

Selinexor combined with R-CHOP achieved a high response rate in newly diagnosed double/triple-hit lymphoma. [PDF]

Blood Adv
Li C, Chen X, Xu J, Lei T, Yu H, Peng S, Han S, Yang H.   +7 more
europepmc   +1 more source

XPO1-dependent nuclear export regulates NS3 localization and promotes DENV-2 replication through mitochondrial remodeling and interferon suppression. [PDF]

Nucleus
Palacios-Rápalo SN, Hernández-Castillo J, De Jesús-González LA, Talamas-Lara D, Cordero-Rivera CD, Cisneros-Vega B, Reyes-Ruiz JM, María Del Ángel R.   +7 more
europepmc   +1 more source

XPO1: From basic research to clinical treatment (Review). [PDF]

Oncol Rep
Yang C, Zhu J, Zheng X, Hou X, Zhao J, Pan Y, Tang Y.   +6 more
europepmc   +1 more source

Preclinical characterization of a reversible XPO1 inhibitor for cancer therapy. [PDF]

Nat Commun
Van Hauwenhuyse J, Reniers F, Persoons L, Noppen S, Wing CE, Niesman AB, Fung HYJ, Vanstreels E, Jacquemyn M, Boel E, Vankerckhoven A, Berckmans Y, Kwanten B, Coosemans A, Van den Mooter G, Chook YM, Dehaen W, Daelemans D.   +17 more
europepmc   +1 more source

Selinexor for multiple myeloma

Australian Prescriber, 2022
openaire   +3 more sources

Progerin Hinders Autophagy Flux at Its Final Stages in Hutchinson-Gilford Progeria Syndrome Cells, Preventing Its Own Autophagic Degradation. [PDF]

Aging Cell
García-Aguirre I, Reyes-Martínez JA, Unzueta J, Guevara-Namorado F, Lizcano-Meneses S, Gonzalo S, Baldan A, Rangel C, Alanis-Funes GJ, Garcia-Sierra F, Ruiz-Fajardo K, Gormes-Pinchanski S, Castro-Obregón S, Meza-Dorantes A, Chavez-Santoscoy RA, Arrieta-Cruz I, Tristán-Aburto P, Magaña JJ, Cisneros B.   +18 more
europepmc   +1 more source

Single agent selinexor is active in patients with myelofibrosis refractory or intolerant to JAK inhibitors. [PDF]

Blood Cancer J
Tantravahi SK, Ellero AA, Patel AB, Parsegov B, Walker CJ, Yap JT, Boucher KM, Rets AV, Prchal JT, Deininger MW.   +9 more
europepmc   +1 more source

Nuclear-Cytoplasmic Axis in Cancer: From Protein Mislocalization to Anticancer Drug Resistance. [PDF]

Oncol Res
Zhu X, He M, Wang L, Su R, Zhong L, Guo T, Wang H, Zou D.   +7 more
europepmc   +1 more source

Selinexor plus tislelizumab in patients with relapsed/refractory natural killer/T-cell lymphoma after failure of PD-1 blockade: the phase 1b TOUCH trial. [PDF]

Oncologist
Liu C, Li D, Gao Y, Zhang W, Guo Z, Zhao J, Huang H, Tao R.   +7 more
europepmc   +1 more source